# National Human Genome Research Institute (NHGRI): Phase 2 study started recruiting, 30 planned (Focal Segmental Glomerulosclerosis, Minimal Change Disease)

**Score:** 75/100

| Field | Value |
|---|---|
| Sponsor | National Human Genome Research Institute (NHGRI) |
| Sponsor type | NIH |
| Study | An Open-Label Phase 2 Study of N-Acetyl-D-Mannosamine (ManNAc) in Subjects With Podocyte Diseases |
| NCT ID | NCT06664814 |
| Phase | Phase 2 |
| Status | recruiting |
| Conditions | Focal Segmental Glomerulosclerosis; Minimal Change Disease; Membranous Nephropathy |
| Intervention types | drug |
| Target enrollment | 30 |
| Site countries | United States |
| Posted | 2024-10-30 |
| Planned start | 2026-10-27 |
| Event | Started recruiting |
| Event date | 2026-10-27 |
| Last update posted | 2026-10-30 |

## Why this score
- Posted in the last two weeks.
- Just started recruiting: sites, recruitment and supply are active.
- Phase 2: multi-site, larger budget.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT06664814). Last refreshed: 2026-11-05T08:46:16.625Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.